INDUSTRY NEWS: Remix Therapeutics reports encouraging clinical progress for its first-in-class MYB mRNA degrader REM-422 - Meet Them In November
INDUSTRY NEWS: Evotec announces a recent CRYO-EM breakthrough using structural biology - Explore These New Approaches in November

Chair’s Closing Remarks

Chair’s Closing Remarks

4:15 pm - Thursday 12th November 2026

Speakers:

Dominic Reynolds

Dominic Reynolds

Chief Scientific Officer

Remix Therapeutics